Ease rules on research into psychedelic drugs, urges David Nutt

Ex-government adviser says substances such as psilocybin could have medical value

Restrictions on the use of psychedelic drugs in research should be relaxed to help find new treatments for conditions including mental health disorders, the former government adviser Prof David Nutt has said.

Nutt was sacked as chair of the advisory committee on the misuse of drugs in October 2009 over his views that ecstasy and LSD are less dangerous than alcohol.

He said the potential benefits of psychedelics – first suggested from research in the 1950s and 60s – were failing to be properly explored because of draconian regulations imposed for political reasons.

While heroin and psilocybin (the active compound in magic mushrooms) are both class A drugs, only the latter is a “schedule 1” controlled drug – a category of drugs deemed to have no medical value.

“The implication is if you want to use [psychedelics] you must be doing something naughty, even though it is research,” said Nutt.

He said the upshot was that research into drugs such as psilocybin involved an expensive and lengthy bureaucratic process to gain licences, and it was also difficult to gain ethical approval.

“You’ve got to get permissions, multiple permissions from the Home Office, and they include inspections,” he told the Guardian, adding that transporting such drugs required special couriers and extensive documentation, and higher levels of security were required than for other drugs that are more harmful.

“A lot of research isn’t done because people just can’t be arsed to go through the rigmarole of getting the licence,” he added.

Despite the tight restrictions, some new research is being conducted, including by Nutt and his team who have conducted brain scans on people who are tripping on LSD.

Writing in the journal Cell, Nutt and colleagues outline evidence suggesting that psilocybin could be a powerful form of therapy for conditions ranging from depression to anorexia.

“Both the depression and tobacco smoking trials have shown that in some people psilocybin can produce clinical remission, in some cases persisting for years,” the team write, adding that they are now working on a trial comparing psilocybin with the antidepressant escitalopram in major depressive disorder.

Nutt and colleagues say psychedelics are thought to produce such results by disrupting activity in the brain involved in habits of thought and behaviour, possibly by interacting with a receptor predominately found in the cerebral cortex of the brain called 5-HT2A.

They say that disruption can not only help individuals gain insights into their conditions during the trip but also provide a window of opportunity in the days that follow, while the participant is experiencing an “afterglow” and thinking differently, for them to engage better with psychotherapy.

However, the team note many questions remain, including how long a trip needs to last for benefits to be seen, whether so-called “microdosing” with the drugs – where levels are so low that there is no trip – could be beneficial, and why some patients relapse after psychedelic therapy.

In the meantime, with psychedelics legal in some parts of the world, the team are hoping to collect data on people’s experiences through an online survey.

Nutt cautioned against people using psychedelics for self-medication, noting that participants in trials were prepared for the trip, and the psychedelics were administered in the presence of therapists.

“Our depressed patients almost always have a very tough trip and we don’t think they’d be safe having a trip like that in the middle of a field or in their own bedroom without professional care,” he said, adding the psychotherapy afterwards was also important to gain benefits.

Ultimately, said Nutt, the schedule 1 restrictions on psychedelics need to change. “We have been arguing for years there should be exemption for research,” he said. “That magic mushrooms can be alongside crack cocaine in [class A] is absurd, but even worse is the putting it in schedule 1 so you can’t use [psychedelics] for research.”

Contributor

Nicola Davis

The GuardianTramp

Related Content

Article image
Ecstasy and cannabis should be freely available for study, says David Nutt

Former government adviser says regulations make it too difficult to research psychoactive drugs with potential medical uses

Alok Jha, science correspondent

31, May, 2012 @6:00 AM

David Nutt row referred to chief scientific adviser
Professor John Beddington to report to PM on freedom of drug advisers to publicly criticise government policy

Alan Travis

11, Nov, 2009 @7:40 PM

Article image
Drugs legislation is hampering clinical research, warns David Nutt
Former government drugs adviser says progress towards new treatments for pain, Parkinson's and depression being blocked

Alok Jha, science correspondent

04, Nov, 2013 @7:09 PM

Article image
Chief drug adviser David Nutt sacked over cannabis stance
Alan Johnson has sacked Professor David Nutt after the scientist renewed his criticism of the government's drug policies

Alan Travis

30, Oct, 2009 @7:41 PM

Article image
David Nutt: my views on drugs classification

David Nutt, the government's former chief drugs adviser, on how he formulated his controversial views on drugs

David Nutt

03, Nov, 2009 @12:05 AM

Article image
‘Curb drink culture’ says drugs expert David Nutt
New restrictions needed for leading cause of deaths of men under 50

Jamie Doward

20, Oct, 2019 @8:12 AM

Article image
Drugs adviser quits over David Nutt cannabis row
Les King resigns from drugs advisory council over government sacking of its head, but reports of second member's resignation unconfirmed

Sam Jones

01, Nov, 2009 @4:35 PM

Article image
Government proposes to scrap need for scientific advice on drugs policy

Amendment removes requirement to appoint at least six scientists to Advisory Council on the Misuse of Drugs

Alok Jha, science correspondent

05, Dec, 2010 @7:24 PM

Article image
Ease restrictions on medical psychedelics to aid research, experts say
Clinical trials suggest psilocybin may be safe for treating depression but government places strict controls on the substance

Ian Sample Science editor

26, Jul, 2020 @11:01 PM

Article image
Is it right to take ecstasy in a TV trial? | David Nutt and Julia Manning

The conversation: Professor David Nutt plans to take MDMA live on Channel 4 to study its effects on the brain. Health campaigner Julia Manning says he risks glamorising the drug

Interview by Oliver Laughland

21, Sep, 2012 @8:00 PM